Clinical Trial: Open Label Study to Evaluate Safety, Tolerability and Efficacy of Evolocumab (AMG 145) in Pediatric Subjects (10 to 17 Years of Age) With Heterozygous Familial Hypercholesterolemia (HeFH) or Homozygous Familial Hypercholesterolemia (HoFH).

Study Status: Recruiting
Recruit Status: Recruiting
Study Type: Interventional

---

Official Title: Open-label, Single-Arm, Multicenter Study to Evaluate the Safety, Tolerability and Efficacy of Evolocumab for LDL-C Reduction, as Add-on to Diet and Lipid-lowering Therapy, in Pediatric Subjects From

Brief Summary: To describe the safety and tolerability of 80 weeks of subcutaneous (SC) evolocumab (AMG 145) when added to standard of care in pediatric subjects 10 to 17 years of age with HeFH or HoFH.